Abstract:656 Background: ARID1A is an essential component of the BAF complex, a large SWI/SNF chromatin-remodeling complex which is implicated in bladder cancer (BC) pathogenesis. While ARID1A mutations are more highly represented in metastatic rather than localized tumors, the biological consequences of ARID1A loss in BC remain to be elucidated. We hypothesize that ARID1A deficiency primes an invasive transformation in BC, thus increasing the likelihood of disease progression and metastases. We used CRISPR/Cas9-mediated gene editing to knockout (KO) the ARID1A gene in several BC cell lines, thus providing a platform for cellular function assays. We show that ARIDA1 loss potentiates an invasive phenotype in these cell lines, giving evidence for its transformative role in the development of higher stage and metastatic BC. Methods: A CRISPR-Cas9 KO was performed with three cell lines with wild-type (WT) ARID1A (T24, SW1710, and 5637). This was accomplished by developing sgRNAs against ARID1A with a GFP marker and carrying out single-cell fluorescence-activated cell sorting (FACS) following nucleofection to identify ARID1A-deficient clones. Western blot analysis was performed on the resulting clones to confirm complete loss of ARID1A. Baseline proliferation studies were performed on the KO and WT cell lines. Finally, invasion studies were performed on the KO and WT cells with a scratch assay. Results: CRISPR-Cas9 directed KO of ARID1A yielded ARID1A-deficient clones for SW1710, T24, and 5637. The proliferation rates for each cell line were analyzed and compared which showed no significant differences. A scratch assay was performed with the cell lines in triplicate, with each ARID1A-deficient cell line showing a trend towards more rapid wound closure than its matched WT cell line (WT=31.5% vs. KO=53.5% for SW1710, p=0.15; WT=17.2% vs. KO=52.0% for T24, p=0.07; WT=10.4% vs. KO=13.9% for 5637, p=0.59). Conclusions: To explore the increased frequency of ARID1A alterations in metastatic BC compared to non-invasive tumors, we developed a model of ARID1A-deficient BC using CRISPR-Cas9. We compared the relative invasiveness of the lines using a scratch assay. All lines trended towards a more invasive phenotype following ARID1A KO, which was especially pronounced in T24. Taken together, these data suggest that ARID1A deficiency in BC may prime tumors for a more invasive phenotype, which may help to explain the higher frequency of ARID1A alterations in higher stage and metastatic samples.

Arid1a Mutation Promotes Cell Proliferation and Invasion, and Leads to Broad Drug Resistance in Colorectal Cancer

ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance

Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer

Neurospora crassa mutants lacking arginino-succinase.

Proteomic insights into the regulatory function of ARID1A in colon cancer cells

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations

Clinicopathologic and Prognostic Relevance of ARID1A Protein Loss in Colorectal Cancer.

ARID1A ablation leads to Multiple Drug Resistance in ovarian cancer via transcriptional activation of MRP2.

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target

ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response

Association of ARID1A deficiency with invasive transformation in metastatic bladder cancer.

ARID1A gene mutation in ovarian and endometrial cancers (Review)

Tumor suppressor role of chromatin-remodeling factor ARID1A]

The Landscape of ARID1A Variants and Correlation with Tumor Mutational Burden in Chinese Solid Tumor Patients.

Loss of ARID1A Expression is Associated with Poor Prognosis in Patients with Gastric Cancer.

Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

"Ultraearly" aneurysm surgery.

ARID1A regulates R-loop associated DNA replication stress